09877.HK
Jenscare Scientific Co., Ltd.
HKSE · Healthcare · Medical - Specialties · CN
HKD 7.40
−1.27%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 146.8M | 88.2M | — | — | — |
| Cost of Revenue | 33.7M | 21.6M | — | — | — |
| Gross Profit | 113.1M | 66.6M | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 184.6M | 173.3M | 142.6K | 288.2M | 291.6M |
| SG&A Expense | 132.9M | 53.4M | 68.2K | 150.3M | 49.6M |
| General & Admin Expense | 28.7M | 24.4M | 68.2K | 150.3M | 49.6M |
| Selling & Marketing Expense | 1.9M | 29.0M | — | — | — |
| Other Expenses | 6.9M | 63.9M | — | — | 170.1M |
| Total Operating Expenses | 324.4M | 290.6M | 210.8K | 438.5M | 511.3M |
| Cost and Expenses | 358.1M | 312.2M | 210.8K | 438.5M | 511.3M |
| Operating Income (EBIT) | (211.3M) | (224.0M) | (210.8K) | (438.5M) | (511.3M) |
| Non-Operating | |||||
| Interest Income | 14.2M | 13.5M | 11.3M | 19.2M | 8.4M |
| Interest Expense | 1.4M | 844.6K | 289.0K | — | 113.0K |
| Net Interest Income | 12.7M | 12.6M | 11.0M | 19.2M | 8.2M |
| Other Non-Op Income/Expense | (23.5M) | (41.6M) | 25.0K | 59.4M | 70.4M |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (234.7M) | (265.6M) | (185.8K) | (379.1M) | (440.9M) |
| Income Tax Expense | — | — | — | — | (1.6M) |
| Bottom Line | |||||
| Net Income | (233.6M) | (264.2M) | (177.5K) | (371.7M) | (439.3M) |
| Earnings from Cont. Ops | (234.7M) | (265.6M) | (185.8K) | (379.1M) | (440.9M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (233.6M) | (264.2M) | (177.5M) | (371.7M) | (439.3M) |
| Per Share | |||||
| Basic EPS | (HK$0.74) | (HK$0.64) | (HK$0.43) | (HK$0.89) | (HK$1.20) |
| Diluted EPS | (HK$0.74) | (HK$0.64) | (HK$0.43) | (HK$0.89) | (HK$1.20) |
| Revenue Per Share | HK$0.35 | HK$0.21 | HK$0.00 | HK$0.00 | HK$0.00 |
| Shares | |||||
| Basic Shares Outstanding | 425.2M | 417.2M | 408.9M | 417.2M | 365.4M |
| Diluted Shares Outstanding | 425.2M | 417.2M | 408.9M | 417.2M | 365.4M |
| Profitability Metrics | |||||
| EBITDA | (191.0M) | (210.2M) | (202.0K) | (429.7M) | (504.8M) |
| D&A | 20.3M | 13.8M | 8.8K | 8.8M | 6.5M |
| EBIT | (211.3M) | (224.0M) | (210.8K) | (438.5M) | (511.3M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026